| Arbor Therapy | |
|
2248 N Alma School Rd Ste 102, Chandler, AZ 85224-2488 | |
| (480) 935-0614 | |
| (480) 393-1968 |
| Full Name | Arbor Therapy |
|---|---|
| Type | Facility |
| Speciality | Speech-language Pathologist |
| Location | 2248 N Alma School Rd Ste 102, Chandler, Arizona |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316464795 | NPI | - | NPPES |
| 412169 | Medicaid | AZ |
| Provider Name | Elizabeth A Nudi |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1750301222 PECOS PAC ID: 6507857778 Enrollment ID: I20040518001407 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
| Provider Name | Jo Ellen Caldwell |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1427178953 PECOS PAC ID: 6800987371 Enrollment ID: I20070813000554 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
| Provider Name | Deborah A Mordhorst |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1003089384 PECOS PAC ID: 1254410277 Enrollment ID: I20080502000009 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
| Provider Name | Amanda K Sullivan |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1750613576 PECOS PAC ID: 8628335007 Enrollment ID: I20171121001191 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
| Provider Name | Amy Grulke |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1164607628 PECOS PAC ID: 7618242728 Enrollment ID: I20180108001380 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
| Provider Name | Tricia A Kiernan |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1114126315 PECOS PAC ID: 6800156183 Enrollment ID: I20180206000467 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
| Provider Name | Carol Ann Parkinson |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1770081382 PECOS PAC ID: 7113288051 Enrollment ID: I20180309001180 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
| Provider Name | Nicole Kavanagh |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1922328780 PECOS PAC ID: 5294077798 Enrollment ID: I20190502002592 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
| Provider Name | Louise A Koziol |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1942320098 PECOS PAC ID: 8123360526 Enrollment ID: I20190506001302 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
| Provider Name | Libby Brandt |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1003933433 PECOS PAC ID: 4183964802 Enrollment ID: I20190510001467 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
| Provider Name | Laura L Fuller |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1255773933 PECOS PAC ID: 0840626339 Enrollment ID: I20200218001596 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
| Provider Name | Sandra L Heide |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1831311554 PECOS PAC ID: 9830526870 Enrollment ID: I20200303002107 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
| Provider Name | Casey M Pond |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1649771452 PECOS PAC ID: 8729499025 Enrollment ID: I20201117002042 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
| Provider Name | Michelle Dorsey |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1235566027 PECOS PAC ID: 5597172700 Enrollment ID: I20210405001546 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
| Provider Name | Sara K Murphy |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1245848159 PECOS PAC ID: 7315356565 Enrollment ID: I20210429001737 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
| Provider Name | Katherine O'brien |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1831729714 PECOS PAC ID: 2264869882 Enrollment ID: I20210601001562 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
| Provider Name | Mikaela Kirby |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1083269625 PECOS PAC ID: 9638578271 Enrollment ID: I20210601002163 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
| Provider Name | Darling Ruiz |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1891247375 PECOS PAC ID: 4385037084 Enrollment ID: I20220201002017 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
| Provider Name | Rachel Stogdill |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1134741408 PECOS PAC ID: 4385023100 Enrollment ID: I20220623003283 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
| Provider Name | Sydney Shultz |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1588199913 PECOS PAC ID: 7315328671 Enrollment ID: I20220718001748 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
| Provider Name | Amanda Aberer |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1639698855 PECOS PAC ID: 0446632145 Enrollment ID: I20220727002870 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
| Provider Name | Sarah Lewis |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1205496759 PECOS PAC ID: 0547642597 Enrollment ID: I20220808001096 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
| Provider Name | Claire A O'connor |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1376116616 PECOS PAC ID: 3577946730 Enrollment ID: I20220820000197 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
| Provider Name | Madeline Kedrowicz |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1942974183 PECOS PAC ID: 7517343189 Enrollment ID: I20221005001041 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
| Provider Name | Jonathan Barsness |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1144612854 PECOS PAC ID: 0547639403 Enrollment ID: I20221215001460 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
| Provider Name | Desiree Meredith |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1942705660 PECOS PAC ID: 6507202199 Enrollment ID: I20240305004264 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Arbor Therapy 2322 W Stottler Dr, Chandler, AZ 85224-2524 Ph: (480) 935-0614 | Arbor Therapy 2248 N Alma School Rd Ste 102, Chandler, AZ 85224-2488 Ph: (480) 935-0614 |
News Archive
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
New research is helping unlock the mystery of how the brain folds as a baby develops in the womb - a process critical to healthy brain function.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.
› Verified 3 days ago
Ms. Heather Marie Liu, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6543 S Teresa Dr, Chandler, AZ 85249 Phone: 480-329-7600 | |
Allison Dawn Smith, MS CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 815 E Warner Rd, Suite 106, Chandler, AZ 85225 Phone: 480-963-5800 Fax: 480-963-5805 | |
Miss Demaurice Jiana Basile, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1525 W Frye Rd, Chandler, AZ 85224 Phone: 480-812-7000 | |
Alicia Rowlett, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3400 N Alma School Rd Apt 2034, Chandler, AZ 85224 Phone: 719-671-7172 | |
Gail Cisneros, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1525 W Frye Rd, Chandler, AZ 85224 Phone: 480-812-7000 | |
Gabrielle Christine Goldsmith, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 964 E Cherry Hills Dr, Chandler, AZ 85249 Phone: 509-217-3367 | |
Lauren Mead, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3160 N Arizona Ave Ste 105, Chandler, AZ 85225 Phone: 480-365-9981 |